--- title: "Rallybio Corporation (NASDAQ:RLYB) Sees Significant Decline in Short Interest" type: "News" locale: "en" url: "https://longbridge.com/en/news/293891443.md" description: "Rallybio Corporation (NASDAQ:RLYB) reported a significant 58.4% decline in short interest for July, dropping to 170,156 shares from June's 408,746. The short-interest ratio stands at 3.5 days, with 3.6% of shares sold short. Additionally, major shareholder Adar1 Capital Management increased its stake, while several hedge funds including Citadel Advisors and Renaissance Technologies boosted their holdings. Analyst consensus remains 'Sell' following recent earnings misses." datetime: "2026-07-27T07:00:30.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/293891443.md) - [en](https://longbridge.com/en/news/293891443.md) - [zh-HK](https://longbridge.com/zh-HK/news/293891443.md) generator: "portal-rs" --- # Rallybio Corporation (NASDAQ:RLYB) Sees Significant Decline in Short Interest Rallybio Corporation (NASDAQ:RLYB - Get Free Report) saw a large decrease in short interest in July. As of July 15th, there was short interest totaling 170,156 shares, a decrease of 58.4% from the June 30th total of 408,746 shares. Based on an average daily trading volume, of 48,124 shares, the days-to-cover ratio is currently 3.5 days. Currently, 3.6% of the shares of the stock are sold short. ## Insider Activity at Rallybio In other Rallybio news, major shareholder Adar1 Capital Management, Llc acquired 120,804 shares of Rallybio stock in a transaction dated Monday, May 4th. The stock was bought at an average cost of $13.97 per share, with a total value of $1,687,631.88. Following the acquisition, the insider owned 744,683 shares of the company's stock, valued at approximately $10,403,221.51. The trade was a 19.36% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last ninety days, insiders have bought 302,473 shares of company stock worth $4,229,715. 10.30% of the stock is currently owned by company insiders. ## Institutional Investors Weigh In On Rallybio A number of hedge funds have recently made changes to their positions in RLYB. XTX Topco Ltd boosted its position in Rallybio by 64.6% in the fourth quarter. XTX Topco Ltd now owns 97,313 shares of the company's stock valued at $67,000 after buying an additional 38,205 shares in the last quarter. Susquehanna International Group LLP increased its holdings in shares of Rallybio by 485.9% during the third quarter. Susquehanna International Group LLP now owns 136,294 shares of the company's stock worth $68,000 after buying an additional 113,031 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Rallybio by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 248,005 shares of the company's stock worth $170,000 after buying an additional 2,996 shares in the last quarter. Citadel Advisors LLC raised its stake in shares of Rallybio by 576.1% in the third quarter. Citadel Advisors LLC now owns 438,705 shares of the company's stock valued at $219,000 after acquiring an additional 373,821 shares during the last quarter. Finally, Renaissance Technologies LLC raised its stake in shares of Rallybio by 16.9% in the fourth quarter. Renaissance Technologies LLC now owns 835,692 shares of the company's stock valued at $573,000 after acquiring an additional 120,892 shares during the last quarter. Institutional investors and hedge funds own 90.34% of the company's stock. ## Rallybio Price Performance Shares of RLYB stock opened at $16.31 on Monday. The stock's fifty day simple moving average is $15.79 and its 200 day simple moving average is $10.70. Rallybio has a one year low of $3.20 and a one year high of $17.57. The firm has a market cap of $86.44 million, a price-to-earnings ratio of -3.76 and a beta of -0.90. Rallybio (NASDAQ:RLYB - Get Free Report) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($1.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by ($0.26). The company had revenue of $0.21 million for the quarter, compared to analyst estimates of $0.21 million. Rallybio had a negative return on equity of 55.79% and a negative net margin of 911.07%. ## Analyst Upgrades and Downgrades Separately, Weiss Ratings restated a "sell (d-)" rating on shares of Rallybio in a research note on Friday, May 8th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of "Sell". **Read Our Latest Stock Report on Rallybio** ## Rallybio Company Profile (Get Free Report) Rallybio Therapeutics, Inc NASDAQ: RLYB is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company's scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio's pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options. Among Rallybio's lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency. ## Featured Stories - Five stocks we like better than Rallybio - RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade? - These 4 Earnings Reports Expose the Market’s Growing Economic Divide - Broadcom May Be the Biggest Winner From Alphabet's Earnings - Volatility Is Back and These 3 Market Tollbooths Are Best Positioned to Profit *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* ## Should You Invest $1,000 in Rallybio Right Now? Before you consider Rallybio, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rallybio wasn't on the list. While Rallybio currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [RLYB.US](https://longbridge.com/en/quote/RLYB.US.md) - [RTX.US](https://longbridge.com/en/quote/RTX.US.md) - [LMT.US](https://longbridge.com/en/quote/LMT.US.md) - [AVGO.US](https://longbridge.com/en/quote/AVGO.US.md) - [GOOGL.US](https://longbridge.com/en/quote/GOOGL.US.md) - [GOOG.US](https://longbridge.com/en/quote/GOOG.US.md) ## Related News & Research - [Rallybio (NASDAQ:RLYB) Major Shareholder Adar1 Capital Management, Llc Acquires 800 Shares](https://longbridge.com/en/news/286420443.md) - [Rallybio Receives Termination Fee After Candid Deal Collapse](https://longbridge.com/en/news/285070480.md) - [$1000 Invested In Veeco Instruments 5 Years Ago Would Be Worth This Much Today](https://longbridge.com/en/news/296657245.md) - [Joby and Archer Are Racing to FAA Certification While Burning Hundreds of Millions a Year. Here's the 1 Number That Picks the Winner.](https://longbridge.com/en/news/296704487.md) - [A Win-Win Deal: Here's Why the Archer Aviation and Boeing Deal Adds Value to Both Stocks](https://longbridge.com/en/news/296748394.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**